Tesamorelin peptide.

What is Tesamorelin?

Tesamorelin stimulates your body's growth-hormone release and reduces deep abdominal fat in the patient groups studied. It is a synthetic peptide made from 44 amino acids, based on growth hormone-releasing hormone, or GHRH. Its best-established use is excess abdominal fat in adults with HIV-associated lipodystrophy. [1]

The main target is visceral fat—fat surrounding the organs inside the abdomen. That is different from the soft layer beneath the skin. A reduction in visceral fat can make the midsection smaller without producing a large change on the scale. The clinical studies measured these compartments separately. [3]

Tesamorelin has also been studied outside HIV: one trial enrolled 60 adults with obesity and reduced growth-hormone secretion. Those participants differ from lean, resistance-trained adults seeking a short cutting cycle. [4]

How Tesamorelin works

Tesamorelin prompts GH release; it does not contain HGH. The response depends on a functioning hormone pathway. The medicine is contraindicated with certain pituitary or hypothalamic disorders, and a higher IGF-1 reading is not automatically a better treatment result. [1]

Tesamorelin benefits

The most consistent body-composition result is less visceral fat. Weight loss, muscle growth, exercise performance and better sleep are separate outcomes. The studies do not turn a change in GH or IGF-1 into proof of every claimed fitness benefit. [1] Tesamorelin benefits and the exact study results →

Daily Tesamorelin dosage

The original clinical trials used 2 mg once daily. Current EGRIFTA WR uses 1.28 mg once daily; EGRIFTA SV uses 1.4 mg once daily. These different numbers come from different formulations and preparation instructions. [1] [6]

Formulation-specific clinical and prescribing information. The 10 mg research vial and pen are separate products; these medicine doses do not establish an equivalent regimen for them. [1] [6]

A syringe marking measures volume. For a 10 mg vial in 2 mL final solution, a 2 mg target corresponds mathematically to 0.4 mL, or 40 units on a U-100 syringe. Changing the solution volume changes that marking. The target-first calculator converts the amount you enter; it does not choose it.

Meal timing, morning versus evening, missed doses and formulation-specific mixing are covered in the dosage and cycles article. The medicine instructions use a daily schedule; five-days-on/two-days-off schedules are not the regimen tested in the pivotal trials. [1]

Tesamorelin cycle length

The main trials assessed results after 26 weeks, with treatment followed out to 52 weeks. A scan-based change was already measurable at 13 weeks in the first trial. These are the useful reference points for interpreting an eight- or twelve-week “cycle” claim. [7] [3]

Deep abdominal fat can return after stopping. The continuation studies do not support treating a short course as a permanent reset. They also do not establish an ideal break length between bodybuilding cycles. [8]

Course quantity and storage life are separate. A nominal supply of peptide may cover several weeks by arithmetic, while the prepared product's usable lifespan can be much shorter. Total milligrams, vials and pens per course →

Tesamorelin vial and prefilled pen

Both formats contain 10 mg total. The vial contains dry powder; the pen contains 3 mL of prepared solution at approximately 3.33 mg/mL. The pen saves the powder-mixing step. It does not contain three times as much peptide because its cartridge holds 3 mL. [9]

Research-labelled products. Drawings show the formats; they are not product photographs.

The vial's concentration depends on the final mixed volume. The pen's concentration is fixed, but its amount per click requires a verified device setting. A U-100 syringe unit and a pen click are different measures. Pen details, storage and measurement →

Tesamorelin results and timeline

The two pivotal trials found approximately 11–15% less visceral fat after six months. The first reported −15.2% with Tesamorelin versus +5.0% with placebo; the second reported −10.9% versus −0.6%. Using both results gives a clearer picture than treating one average as a guaranteed outcome. [2] [3]

The large studies primarily enrolled adults with HIV-associated abdominal fat. The smaller non-HIV study enrolled adults with obesity and low GH secretion. Those settings matter when judging claims aimed at already-lean gym users. [4] Measured before-and-after results at 13, 26 and 52 weeks →

Tesamorelin side effects

Recognized effects in EGRIFTA prescribing information. The detailed safety article gives trial percentages, placebo comparisons and symptom-specific actions. [1]

Active cancer, pregnancy and certain disorders of the pituitary–hypothalamic pathway are contraindications for the medicine. Glucose status, IGF-1 and other medication use need review before and during prescribed treatment. Tesamorelin side effects, testing and interactions →

Tesamorelin COA and product documentation

The batch certificate is pending. No Tesamorelin lot number, measured purity, vial-content assay or finished-pen test result is published here without the corresponding report. The product comparison includes the confirmed format, strength, vehicle and storage details. Product specifications and COA status →